Empagliflozin Reduces Blood Pressure in Patients With Type 2 Diabetes and Hypertension
The DOI matches its Crossref record; 33 of the 35 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To investigate the efficacy, safety, and tolerability of empagliflozin in patients with type 2 diabetes and hypertension. RESEARCH DESIGN AND METHODS: Patients (N = 825) with type 2 diabetes and hypertension (mean seated systolic blood pressure [SBP] 130–159 mmHg and diastolic blood pressure [DBP] 80–99 mmHg) were randomized (double blind) to 10 mg or 25 mg empagliflozin or placebo once daily for 12 weeks. RESULTS: At week 12, adjusted mean difference versus placebo in change from baseline in mean 24-h SBP (ambulatory blood pressure monitoring [ABPM]) was −3.44 mmHg (95% CI −4.78, −2.09) with 10 mg empagliflozin and −4.16 mmHg (−5.50, −2.83) with 25 mg empagliflozin (both P < 0.001). At week 12, adjusted mean difference versus placebo in change from baseline in mean 24-h DBP (ABPM) was −1.36 mmHg (95% CI −2.15, −0.56) with 10 mg empagliflozin and −1.72 mmHg (95% CI −2.51, −0.93) with 25 mg empagliflozin (both P < 0.001). Changes in office BP were consistent with ABPM. Adjusted mean difference versus placebo in change from baseline in HbA1c at week 12 was −0.62% (95% CI −0.72, −0.52) (−6.8 mmol/mol [95% CI −7.9, −5.7]) with 10 mg empagliflozin and −0.65% (95% CI −0.75, −0.55) (−7.1 mmol/mol [95% CI −8.2, −6.0]) with 25 mg empagliflozin (both P < 0.001). Empagliflozin was well tolerated. One patient on placebo and one patient on 10 mg empagliflozin reported events consistent with volume depletion. CONCLUSIONS: Empagliflozin was associated with significant and clinically meaningful reductions in BP and HbA1c versus placebo and was well tolerated in patients with type 2 diabetes and hypertension.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the EMPA-REG BP trial, empagliflozin reduced mean 24 hour ambulatory systolic BP by approximately 3-4 mmHg after 12 weeks, 16 with consistent reductions irrespective of the number of background BP lowering drugs.17”
From Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease: Insights From the CREDENCE Trial (2021) · cites this paper as [16]
Citations
Cites
Chobanian, A. V. (2003) · JAMA · doi:10.1001/jama.289.19.2560 · Cited by 25,386
(2013) · European Heart Journal · doi:10.1093/eurheartj/eht151 · Cited by 13,655
Chobanian, A. V., Bakris, G. L., Black, H. R., Cushman, W. C., Green, L. A., Izzo, J. L., Jones, D. W., Materson, B. J., Oparil, S., Wright, J. T., et al. (2003) · Hypertension · doi:10.1161/01.hyp.0000107251.49515.c2 · Cited by 13,271
James, P. A., Oparil, S., Carter, B. L., Cushman, W. C., Dennison-Himmelfarb, C., Handler, J., Lackland, D. T., LeFevre, M. L., MacKenzie, T. D., Ogedegbe, O., et al. (2014) · JAMA · doi:10.1001/jama.2013.284427 · Cited by 7,950
Stearne, M. R., Palmer, S. L., Hammersley, M. S., Franklin, S. L., Spivey, R. S., Lévy, J., Tidy, C. R., Bell, N. J., Steemson, J., Barrow, B. A., et al. (1998) · UCL Discovery (University College London) · Cited by 6,090
Mancia, G., De Backer, G., Dominiczak, A., Cifkova, R., Fagard, R., Germano, G., Grassi, G., Heagerty, A. M., Kjeldsen, S. E., Laurent, S., et al. (2007) · Journal of Hypertension · doi:10.1097/hjh.0b013e3281fc975a · Cited by 5,824
Hansson, L., Zanchetti, A., Carruthers, S. G., Dahlöf, B., Elmfeldt, D., Julius, S., Ménard, J., Rahn, K. H., Wedel, H., & Westerling, S. (1998) · The Lancet · doi:10.1016/s0140-6736(98)04311-6 · Cited by 5,728 · cited 1×
“Randomized controlled trials have shown reductions in major cardiovascular events when SBP was lowered to ,150 mmHg and DBP was lowered to # 85 mmHg in patients with diabetes (23,24).”
BackgroundInzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919
Cited by
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Self-citationEmpagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Wanner, C., Inzucchi, S. E., Lachin, J. M., Fitchett, D., von Eynatten, M., Mattheus, M., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Zinman, B. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1515920 · Cited by 3,655
Self-citationThe Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019)
Umemura, S., Arima, H., Arima, S., Asayama, K., Dohi, Y., Hirooka, Y., Horio, T., Hoshide, S., Ikeda, S., Ishimitsu, T., et al. (2019) · Hypertension Research · doi:10.1038/s41440-019-0284-9 · Cited by 1,880
Chait, A., & den Hartigh, L. J. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.00022 · Cited by 1,529
“Empagliflozin also is associated with decreased hypertension, reduced arterial stiffness, and decreased vascular resistance (594, 595).”
BackgroundHeerspink, H. J. L., Perkins, B. A., Fitchett, D. H., Husain, M., & Cherney, D. Z. I. (2016) · Circulation · doi:10.1161/circulationaha.116.021887 · Cited by 1,376
Fitchett, D., Zinman, B., Wanner, C., Lachin, J. M., Hantel, S., Salsali, A., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Inzucchi, S. E. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv728 · Cited by 907
Self-citationEmpagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
(2016) · New England Journal of Medicine · doi:10.1056/nejmc1600827 · Cited by 700
Chilton, R., Tikkanen, I., Cannon, C. P., Crowe, S., Woerle, H. J., Broedl, U. C., & Johansen, O. E. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12572 · Cited by 507
“Patients underwent 24-h ABPM ≤7 days before randomization and at week 12 [27].”
BackgroundMethodResultInfluentialSelf-citationLytvyn, Y., Bjornstad, P., Udell, J. A., Lovshin, J. A., & Cherney, D. Z. I. (2017) · Circulation · doi:10.1161/circulationaha.117.030012 · Cited by 459
SGLT-2 inhibitors and cardiovascular risk: Proposed pathways and review of ongoing outcome trials
Inzucchi, S. E., Zinman, B., Wanner, C., Ferrari, R., Fitchett, D., Hantel, S., Espadero, R.-M., Woerle, H.-J., Broedl, U. C., & Johansen, O. E. (2015) · Diabetes and Vascular Disease Research · doi:10.1177/1479164114559852 · Cited by 399
Self-citationPharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus
Tahrani, A. A., Barnett, A. H., & Bailey, C. J. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.86 · Cited by 398
Mazidi, M., Rezaie, P., Gao, H., & Kengne, A. P. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.116.004007 · Cited by 347
“Data were sorted by first author, year of publication, country of the study, design, age range of the participants, total sample size, SGLT2 inhibitor, comparator, number of patients, dosage, and follow-up duration (Table 1).(13-55)”
Toyama, T., Neuen, B. L., Jun, M., Ohkuma, T., Neal, B., Jardine, M. J., Heerspink, H. L., Wong, M. G., Ninomiya, T., Wada, T., et al. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13648 · Cited by 330
Carbohydrate-based drugs launched during 2000−2021
Cao, X., Du, X., Jiao, H., An, Q., Chen, R., Fang, P., Wang, J., & Yu, B. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.05.020 · Cited by 267
Habibi, J., Aroor, A. R., Sowers, J. R., Jia, G., Hayden, M. R., Garro, M., Barron, B., Mayoux, E., Rector, R. S., Whaley-Connell, A., et al. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0489-z · Cited by 262
“5 mmHg, respectively compared to placebo), as well as indirect markers of arterial stiffness and vascular resistance [41, 60].”
BackgroundResultWeber, M. A., Mansfield, T. A., Cain, V. A., Iqbal, N., Parikh, S., & Ptaszynska, A. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00417-9 · Cited by 254
Kario, K., Okada, K., Kato, M., Nishizawa, M., Yoshida, T., Asano, T., Uchiyama, K., Niijima, Y., Katsuya, T., Urata, H., et al. (2019) · Circulation · doi:10.1161/circulationaha.118.037076 · Cited by 251
Cherney, D. Z. I., Cooper, M. E., Tikkanen, I., Pfarr, E., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Lund, S. S. (2018) · Kidney International · doi:10.1016/j.kint.2017.06.017 · Cited by 243
Self-citationMa, J., Li, Y., Yang, X., Liu, K., Zhang, X., Zuo, X., Ye, R., Wang, Z., Shi, R., Meng, Q., et al. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01430-7 · Cited by 243
Zinman, B., Inzucchi, S. E., Lachin, J. M., Wanner, C., Ferrari, R., Fitchett, D., Bluhmki, E., Hantel, S., Kempthorne-Rawson, J., Newman, J., et al. (2014) · Cardiovascular Diabetology · doi:10.1186/1475-2840-13-102 · Cited by 239
Self-citationHalden, T. A. S., Kvitne, K. E., Midtvedt, K., Rajakumar, L., Robertsen, I., Brox, J., Bollerslev, J., Hartmann, A., Åsberg, A., & Jenssen, T. (2019) · Diabetes Care · doi:10.2337/dc19-0093 · Cited by 231
“Empagliflozin reduces blood pressure in patients with type 2 diabetes (35,36).”
BackgroundEmpagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials
Levine, M. J. (2017) · Current Diabetes Reviews · doi:10.2174/1573399812666160613113556 · Cited by 230
“Empagliflozin has also been assessed in special subpopulations with T2DM, including patients with chronic kidney disease (CKD) [25, 31], hypertension [32, 33], high risk of cardiovascular disease [34], or obesity [35], as well as in elderly patients [36] and Japanese patients [37] (Table 3).”
BackgroundSchork, A., Saynisch, J., Vosseler, A., Jaghutriz, B. A., Heyne, N., Peter, A., Häring, H.-U., Stefan, N., Fritsche, A., & Artunc, F. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0852-y · Cited by 227
Donnan, J. R., Grandy, C. A., Chibrikov, E., Marra, C. A., Aubrey-Bassler, K., Johnston, K., Swab, M., Hache, J., Curnew, D., Nguyen, H., et al. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-022577 · Cited by 222
Hypertension management in patients with cardiovascular comorbidities
Lauder, L., Mahfoud, F., Azizi, M., Bhatt, D. L., Ewen, S., Kario, K., Parati, G., Rossignol, P., Schlaich, M. P., Teo, K. K., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehac395 · Cited by 210
Tang, H., Dai, Q., Shi, W., Zhai, S., Song, Y., & Han, J. (2017) · Diabetologia · doi:10.1007/s00125-017-4370-8 · Cited by 206
Baker, W. L., Buckley, L. F., Kelly, M. S., Bucheit, J. D., Parod, E. D., Brown, R., Carbone, S., Abbate, A., & Dixon, D. L. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.117.005686 · Cited by 204
“…1.7 78.6 1.3 NR NR ERTU 5 mg/d 38 53.8 9.9 135.0 1.9 80.1 1.4 ERTU 25 mg/d 39 52.5 6.6 135.5 1.9 80.3 1.3 Placebo 38 55.1 6.7 136.1 2.5 81.8 1.5 Tikkanen et al (2015)19 R, DB, PC EMPA 10 mg/d 276 12 60.6 8.5 131.3 13.0 75.1 8.3 NR NR EMPA 25 mg/d 276 59.9 9.7 131.2 12.1 74.6 7.5 Placebo 271…”
BackgroundInfluentialLee, H.-C., Shiou, Y.-L., Jhuo, S.-J., Chang, C.-Y., Liu, P.-L., Jhuang, W.-J., Dai, Z.-K., Chen, W.-Y., Chen, Y.-F., & Lee, A.-S. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0849-6 · Cited by 204
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Wanner, C., Inzucchi, S. E., & Zinman, B. (2016) · New England Journal of Medicine · doi:10.1056/nejmc1611290 · Cited by 199
Kohler, S., Zeller, C., Iliev, H., & Kaspers, S. (2017) · Advances in Therapy · doi:10.1007/s12325-017-0573-0 · Cited by 195
Self-citationThe Evolving Understanding and Approach to Residual Cardiovascular Risk Management
Dhindsa, D. S., Sandesara, P. B., Shapiro, M. D., & Wong, N. D. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.00088 · Cited by 192
“The possible explanations for these observations include osmotic diuresis leading to improved cardiac hemodynamics by reduction in left ventricular preload, lowering of body weight due to calorie and fluid losses, and lowering of blood pressure (103, 104).”
BackgroundThe current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management
Xu, B., Li, S., Kang, B., & Zhou, J. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01512-w · Cited by 190
Empagliflozin attenuates diabetic tubulopathy by improving mitochondrial fragmentation and autophagy
Lee, Y. H., Kim, S. H., Kang, J. M., Heo, J. H., Kim, D.-J., Park, S. H., Sung, M., Kim, J., Oh, J., Yang, D. H., et al. (2019) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00565.2018 · Cited by 189
Scheen, A. J. (2015) · Clinical Pharmacokinetics · doi:10.1007/s40262-015-0264-4 · Cited by 182
“Small decreases in eGFR were seen in the 25-mg empagliflozin group, which returned to baseline at follow-up [57].”
BackgroundEmpagliflozin: A Review in Type 2 Diabetes
Frampton, J. E. (2018) · Drugs · doi:10.1007/s40265-018-0937-z · Cited by 171
“EMPA-REG BP [20] (12) EMP 10 (276) − 0.”
BackgroundMethodInsulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease
Lo, C., Toyama, T., Wang, Y., Lin, J., Hirakawa, Y., Jun, M., Cass, A., Hawley, C. M., Pilmore, H., Badve, S. V., et al. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011798.pub2 · Cited by 100
Kusaka, H., Koibuchi, N., Hasegawa, Y., Ogawa, H., & Kim-Mitsuyama, S. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0473-7 · Cited by 155
“Effects of empagliflozin on blood pressure Convincing evidence [11, 21, 26] indicates that SGLT2 inhibitors including empagliflozin significantly reduce BP in type 2 diabetic patients and natriuretic action of SGLT2 inhibitors is postulated to participate in BP reduction.”
BackgroundNeeland, I. J., McGuire, D. K., Chilton, R., Crowe, S., Lund, S. S., Woerle, H. J., Broedl, U. C., & Johansen, O. E. (2016) · Diabetes and Vascular Disease Research · doi:10.1177/1479164115616901 · Cited by 168
Self-citationTeodoro, J. S., Nunes, S., Rolo, A. P., Reis, F., & Palmeira, C. M. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2018.01857 · Cited by 164
Blood pressure control in type 2 diabetic patients
Grossman, A., & Grossman, E. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0485-3 · Cited by 161
“The Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG) BP study [111] reported that mean systolic BP as evaluated by ambulatory BP monitoring was significantly lower in patients treated with both 10 and 25 mg empagliflozin compared with placebo.”
BackgroundInflammatory Mechanisms of Diabetes and Its Vascular Complications
Nedosugova, L. V., Markina, Y. V., Бочкарева, Л. А., Кузина, И. А., Petunina, N. A., Yudina, I. Y., & Kirichenko, T. V. (2022) · Biomedicines · doi:10.3390/biomedicines10051168 · Cited by 156
Liu, Z., Ma, X., Ilyas, I., Zheng, X., Luo, S., Little, P. J., Kamato, D., Sahebkar, A., Wu, W., Weng, J., et al. (2021) · Theranostics · doi:10.7150/thno.54498 · Cited by 155
Arterial hypertension – Clinical trials update 2021
Ghorani, H. A., Götzinger, F., Böhm, M., & Mahfoud, F. (2021) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2021.09.007 · Cited by 154
“Additionally, recent studies showed that SGLT2 inhibitors and GLP1-RAs exhibit BP lowering effects [37,38].”
Stanciu, S. M., Rusu, E., Miricescu, D., Radu, A. C., Axinia, B., Vrabie, A.-M., Ionescu, R. F., Jinga, M., & Sîrbu, C. A. (2023) · Metabolites · doi:10.3390/metabo13010087 · Cited by 144
Sánchez‐García, A., Simental-Mendía, M. A., Millán-Alanís, J. M., & Simental‐Mendía, L. E. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105068 · Cited by 140
On behalf of the EMPA-REG EXTEND™ MONO investigators, Roden, M., Merker, L., Christiansen, A. V., Roux, F., Salsali, A., Kim, G., Stella, P., Woerle, H. J., & Broedl, U. C. (2015) · Cardiovascular Diabetology · doi:10.1186/s12933-015-0314-0 · Cited by 127
“In previous Phase III studies, empagliflozin reduced SBP compared with placebo [8–12, 15, 21].”
BackgroundSelf-citationGeorgianos, P. I., & Agarwal, R. (2019) · Diabetes Care · doi:10.2337/dc18-2207 · Cited by 130
“studies used dapagliflozin administered at a single dose of 10 mg/day (10,11,14,15), one study used empagliflozin administered at doses of 10 and 25 mg/day (12), one study used canagliflozin at doses of 100 and 300 mg/day (13), and one study used ertugliflozin at doses ranging from 1 to 25 mg/day (9).”
BackgroundMancia, G., Cannon, C. P., Tikkanen, I., Zeller, C., Ley, L., Woerle, H. J., Broedl, U. C., & Johansen, O. E. (2016) · Hypertension · doi:10.1161/hypertensionaha.116.07703 · Cited by 128
Self-citationHypertension in patients with type 2 diabetes mellitus: Targets and management
Pavlou, D. I., Paschou, S. Α., Anagnostis, P. G., Spartalis, Μ., Spartalis, E. D., Vryonidou, A., Tentolouris, N., & Siasos, G. (2018) · Maturitas · doi:10.1016/j.maturitas.2018.03.013 · Cited by 126
Effect of SGLT2 Inhibitors on the Sympathetic Nervous System and Blood Pressure
Scheen, A. J. (2019) · Current Cardiology Reports · doi:10.1007/s11886-019-1165-1 · Cited by 122
Kovács, C. S., Seshiah, V., Merker, L., Christiansen, A. V., Roux, F., Salsali, A., Kim, G., Stella, P., Woerle, H., & Broedl, U. C. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.05.511 · Cited by 122
Self-citationMajewski, C., & Bakris, G. L. (2015) · Diabetes Care · doi:10.2337/dc14-1596 · Cited by 115
“(4) investigate the effectiveness and safety of the newest agent in this class, empagliflozin, on blood pressure”
BackgroundResultKawasoe, S., Maruguchi, Y., Kajiya, S., Uenomachi, H., Miyata, M., Kawasoe, M., Kubozono, T., & Ohishi, M. (2017) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-017-0125-x · Cited by 109
“There are several findings showing that SGLT2 inhibitors decrease BP [12, 13].”
BackgroundSGLT2 inhibitors and cardioprotection: a matter of debate and multiple hypotheses
Filippatos, T. D., Liontos, A., Papakitsou, I., & Elisaf, M. (2019) · Postgraduate Medicine · doi:10.1080/00325481.2019.1581971 · Cited by 117
The Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Sympathetic Nervous Activity
Wan, N., Rahman, A., Hitomi, H., & Nishiyama, A. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00421 · Cited by 115
“Similarly, treatment with empagliflozin for 12 weeks resulted in a greater BP reduction in hypertensive patients with type 2 diabetic who exhibited higher baseline BP (17).”
BackgroundYe, N., Jardine, M. J., Oshima, M., Hockham, C., Heerspink, H. J. L., Agarwal, R., Bakris, G., Schutte, A. E., Arnott, C., Chang, T. I., et al. (2021) · Circulation · doi:10.1161/circulationaha.120.048740 · Cited by 115
Direct cardiovascular impact of SGLT2 inhibitors: mechanisms and effects
Kaplan, A., Abidi, E., EL‐Yazbi, A. F., Eid, A. H., Booz, G. W., & Zouein, F. A. (2018) · Heart Failure Reviews · doi:10.1007/s10741-017-9665-9 · Cited by 114
“Speculations on the basis of such effects included a role for the observed reduction of BP, body weight, and increased diuretic effects (see box for EMPA-REG Outcome Tria l Summary) [32] .”
BackgroundNishimura, R., Tanaka, Y., Koiwai, K., Inoue, K., Hach, T., Salsali, A., Lund, S. S., & Broedl, U. C. (2015) · Cardiovascular Diabetology · doi:10.1186/s12933-014-0169-9 · Cited by 106
Self-citationOrtega, R., Collado, A., Selles, F., Navarro, H. G., Sanz, M., Real, J. T., & Piqueras, L. (2019) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.119.312659 · Cited by 113
SGLT2 Inhibitors and Ketone Metabolism in Heart Failure
Saucedo‐Orozco, H., Voorrips, S. N., Yurista, S. R., de Boer, R. A., & Westenbrink, B. D. (2022) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2022.11.1.1 · Cited by 114
Monami, M., Nreu, B., Zannoni, S., Lualdi, C., & Mannucci, E. (2017) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.04.017 · Cited by 111
Hypertension and Heart Failure: From Pathophysiology to Treatment
Gallo, G., & Savoia, C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25126661 · Cited by 112
Ferdinand, K. C., Izzo, J. L., Lee, J., Meng, L., George, J., Salsali, A., & Seman, L. (2019) · Circulation · doi:10.1161/circulationaha.118.036568 · Cited by 105
Self-citationSpotlight on ertugliflozin and its potential in the treatment of type 2 diabetes: evidence to date
Cinti, F., Moffa, S., Impronta, F., Cefalo, C. M. A., Sun, V. A., Sorice, G. P., Mezza, T., & Giaccari, A. (2017) · Drug Design, Development and Therapy · doi:10.2147/dddt.s114932 · Cited by 91
Bae, J. H., Park, E.-G., Kim, S., Kim, S. G., Hahn, S., & Kim, N. H. (2019) · Scientific Reports · doi:10.1038/s41598-019-49525-y · Cited by 106
Zanchi, A., Burnier, M., Muller, M., Wurzner-Ghajarzadeh, A., Maillard, M. P., Loncle, N., Milani, B., Dufour, N., Bonny, O., & Pruijm, M. T. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.016173 · Cited by 106
Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Clinician’s Guide
Simes, B. C., & MacGregor, G. G. (2019) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s212003 · Cited by 103
Zou, C.-Y., Liu, X.-K., Sang, Y.-Q., Wang, B., & Liang, J. (2019) · Medicine · doi:10.1097/md.0000000000018245 · Cited by 85
Jordan, J., Tank, J., Heusser, K., Heise, T., Wanner, C., Heer, M., Macha, S., Mattheus, M., Lund, S. S., Woerle, H. J., et al. (2017) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2017.07.005 · Cited by 102
Self-citationMonami, M., Dicembrini, I., & Mannucci, E. (2016) · Acta Diabetologica · doi:10.1007/s00592-016-0892-7 · Cited by 99
SGLT2 inhibitors: their potential reduction in blood pressure
Maliha, G., & Townsend, R. R. (2014) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2014.11.001 · Cited by 97
“Studies looking specifically at the antihypertensive effect of empagliflozin observed that urine volumes return to pretreatment levels after 12 weeks with chronic dosing, although blood pressure effects remain relatively similar, implying that direct diuresis (whether by sodium or glucose loss) cannot be the only mech…”
BackgroundHeise, T., Jordan, J., Wanner, C., Heer, M. A., Macha, S., Mattheus, M., Lund, S. S., Woerle, H. J., & Broedl, U. C. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2016.09.001 · Cited by 96
Self-citationColacci, M., Fralick, J., Odutayo, A., & Fralick, M. (2022) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2021.04.006 · Cited by 94
Neeland, I. J., Eliasson, B., Kasai, T., Marx, N., Zinman, B., Inzucchi, S. E., Wanner, C., Zwiener, I., Wojeck, B. S., Yaggi, H. K., et al. (2020) · Diabetes Care · doi:10.2337/dc20-1096 · Cited by 93
Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes
Kohler, S., Salsali, A., Hantel, S., Kaspers, S., Woerle, H. J., Kim, G., & Broedl, U. C. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2016.03.031 · Cited by 88
Self-citationHypertension: Current trends and future perspectives
Hunter, P. G., Chapman, F. A., & Dhaun, N. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14825 · Cited by 93
“Empagliflozin was well tolerated.(60) A larger BP reduction was reported by the SACRA trialists, where 132 nonobese elderly Japanese patients with uncontrolled nocturnal hypertension (SBP ≥ 115 mmHg between 0200 and 0400) were randomised to receive empagliflozin (10 mg) or placebo in addition to stable baseline angiot…”
BackgroundZhang, Q., Zhou, S., & Liu, L. (2023) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-01092-z · Cited by 90
Targeting Mitochondrial Calcium Handling and Reactive Oxygen Species in Heart Failure
Dietl, A., & Maack, C. (2017) · Current Heart Failure Reports · doi:10.1007/s11897-017-0347-7 · Cited by 90
Nocturnal Hypertension and Heart Failure: Mechanisms, Evidence, and New Treatments
Kario, K., & Williams, B. (2021) · Hypertension · doi:10.1161/hypertensionaha.121.17440 · Cited by 82
Townsend, R. R., Machin, I., Ren, J., Trujillo, A., Kawaguchi, M., Vijapurkar, U., Damaraju, C. V., & Pfeifer, M. (2016) · The Journal of Clinical Hypertension · doi:10.1111/jch.12747 · Cited by 85
Seidu, S., Kunutsor, S. K., Cos, X., Gillani, S., & Khunti, K. (2018) · Primary Care Diabetes · doi:10.1016/j.pcd.2018.02.001 · Cited by 82
SGLT2 inhibitors in patients with type 2 diabetes and renal disease: overview of current evidence
Davidson, J. A. (2019) · Postgraduate Medicine · doi:10.1080/00325481.2019.1601404 · Cited by 82
Resistant Hypertension: Disease Burden and Emerging Treatment Options
Flack, J. M., Buhnerkempe, M., & Moore, K. T. (2024) · Current Hypertension Reports · doi:10.1007/s11906-023-01282-0 · Cited by 82
Kashiwagi, A., & Maegawa, H. (2017) · Journal of Diabetes Investigation · doi:10.1111/jdi.12644 · Cited by 82
Shao, S., Chang, K., Hung, M., Yang, N.-I., Chan, Y., Chen, H., Yang, Y. K., & Lai, E. C. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0919-9 · Cited by 81
New Diabetes Therapies and Diabetic Kidney Disease Progression: the Role of SGLT-2 Inhibitors
Dekkers, C. C. J., Gansevoort, R. T., & Heerspink, H. J. L. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-0992-6 · Cited by 81
Obesity and hypertension in Latin America: Current perspectives
Ruilope, L. M., Filho, A. C. B. N., Nadruz, W., Rosales, F. F. R., & Verdejo-París, J. (2018) · Hipertensión y Riesgo Vascular · doi:10.1016/j.hipert.2017.12.004 · Cited by 79
A Comprehensive Review on Weight Loss Associated with Anti-Diabetic Medications
Haddad, F., Dokmak, G., Bader, M., & Karaman, R. (2023) · Life · doi:10.3390/life13041012 · Cited by 79
“823 T2DM patients (cohort 1) were randomly assigned to receive either empagliflozin 10 mg, empagliflozin 25 mg, or a placebo every day for 12 weeks [95].”
MethodMichel, M. C., Mayoux, E., & Vallon, V. (2015) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-015-1134-1 · Cited by 78
“…to placebo or sitagliptin treatment have also been observed in response to empagliflozin in phase III studies, in which reductions within the hypertensive subgroup were greater than in the overall population (Roden et al. 2013; Häring et al. 2013, 2014; Kovacs et al. 2014; Tikkanen et al. 2015).”
ResultImpact of sodium–glucose cotransporter 2 inhibitors on blood pressure
Reed, J. (2016) · Vascular Health and Risk Management · doi:10.2147/vhrm.s111991 · Cited by 64
Comprehensive renoprotective effects of ipragliflozin on early diabetic nephropathy in mice
Kamezaki, M., Kusaba, T., Komaki, K., Fushimura, Y., Watanabe, N., Ikeda, K., Kitani, T., Yamashita, N., Uehara, M., Kirita, Y., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-22229-5 · Cited by 73
Saad, M. S., Mahmoud, A. N., Elgendy, I. Y., Abu‐Zaid, A., Barakat, A. F., Elgendy, A. Y., Al‐Ani, M. A., Mentias, A. G., Nairooz, R. S., Bavry, A. A., et al. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.11.181 · Cited by 76
Imprialos, K. P., Sarafidis, P. A., & Karagiannis, A. I. (2015) · Journal of Hypertension · doi:10.1097/hjh.0000000000000719 · Cited by 71
“[91] investigated the efficacy of empagliflozin vs placebo as additional therapy to other oral antidiabetic agents with or without insulin.”
BackgroundControl of 24-hour blood pressure with SGLT2 inhibitors to prevent cardiovascular disease
Kario, K., Ferdinand, K. C., & O’Keefe, J. H. (2020) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2020.04.003 · Cited by 71
SGLT2 inhibition: efficacy and safety in type 2 diabetes treatment
Scheen, A. J. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.1100167 · Cited by 70
“001).[81] Changes in office blood pressure were consistent with ambulatory blood pressure monitoring.”
ResultChawla, G., & Chaudhary, K. K. (2019) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2019.04.035 · Cited by 69
Natale, P., Tunnicliffe, D. J., Toyama, T., Palmer, S. C., Saglimbene, V. M., Ruospo, M., Gargano, L., Stallone, G., Gesualdo, L., & Strippoli, G. F. (2024) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015588.pub2 · Cited by 69
Kimura, G. (2016) · Circulation Journal · doi:10.1253/circj.cj-16-0780 · Cited by 65
Abdurrachim, D., Teo, X. Q., Woo, C. C., Chan, W. X., Lalic, J., Lam, C. S. P., & Lee, P. T. H. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13536 · Cited by 68
“The effects of empagliflozin on myocardial ketone body utilization were accompanied by a lower systolic blood pressure in SHHF-EMPA rats, which is in agreement with observations in patients with diabetes and hypertension.(23,24) Lower blood pressure decreases cardiac afterload and oxygen consumption (MVO2), which may…”
ResultSingh, J. S., Fathi, A., Vickneson, K., Mordi, I. R., Mohan, M., Houston, J. G., Pearson, E. R., Struthers, A. D., & Lang, C. C. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0419-0 · Cited by 67
“Additionally, SGLT2 inhibitors also reduce blood pressure by reducing arterial stiffness [29], and indirectly, as a result of increased diuresis [39, 40].”
Background
Metadata
- Authors
- Tikkanen, I., Narko, K., Zeller, C., Green, A., Salsali, A., Broedl, U. C., & Woerle, H. J.
- Affiliations
- Helsinki University Hospital (FI)
- Boehringer Ingelheim (Finland) (FI)
- Boehringer Ingelheim (Germany) (DE)
- inVentiv Health Clinical (CA)
- Corresponding author
- Tikkanen, Ilkka
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2014-09-30
- Volume
- 38
- Issue
- 3
- Pages
- 420-428
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2138173919
- Cited by
- 468
- References
- 35
- Citations by year
- 2026: 19 · 2025: 29 · 2024: 27 · 2023: 41 · 2022: 39 · 2021: 38 · 2020: 41 · 2019: 50 · 2018: 44 · 2017: 52 · 2016: 53 · 2015: 31 · 2014: 3
- FWCI
- 31.78
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Boehringer Ingelheim
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Keywords
- empagliflozin, type 2 diabetes, hypertension, blood pressure reduction, SGLT2 inhibitors, ambulatory blood pressure monitoring, glycemic control, HbA1c, tolerability, adverse events, dose comparison, antihypertensive therapy, renin-angiotensin system blockade
- MeSH terms
- Analysis of Variance, Antihypertensive Agents, Benzhydryl Compounds, Blood Pressure, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Double-Blind Method, Drug Administration Schedule, Female, Glucosides, Glycated Hemoglobin, Humans, Hypertension, Hypoglycemic Agents, Male, Middle Aged, Weight Loss, Treatment Outcome, Blood Pressure Monitoring, Ambulatory
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.